Selective and potent COX-2 inhibitor (in vitro
values are 0.005 and 140 μ
M for human recombinant COX-2 and COX-1 respectively). Displays potent anti-inflammatory activity in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
4-[5-methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2.
Talley et al.
A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.
Walker et al.
Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
Gierse et al.